UroGen Pharma (URGN) Equity Average (2019 - 2025)
Historic Equity Average for UroGen Pharma (URGN) over the last 7 years, with Q3 2025 value amounting to -$104.4 million.
- UroGen Pharma's Equity Average fell 47397.05% to -$104.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.4 million, marking a year-over-year decrease of 47397.05%. This contributed to the annual value of -$37.0 million for FY2024, which is 5211.65% up from last year.
- Per UroGen Pharma's latest filing, its Equity Average stood at -$104.4 million for Q3 2025, which was down 47397.05% from -$69.9 million recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Equity Average registered a high of $86.4 million during Q1 2021, and its lowest value of -$127.5 million during Q2 2023.
- Its 5-year average for Equity Average is -$28.6 million, with a median of -$29.0 million in 2022.
- Per our database at Business Quant, UroGen Pharma's Equity Average tumbled by 227749.68% in 2023 and then surged by 13094.27% in 2024.
- UroGen Pharma's Equity Average (Quarter) stood at $20.0 million in 2021, then crashed by 482.1% to -$76.3 million in 2022, then increased by 29.77% to -$53.6 million in 2023, then skyrocketed by 115.59% to $8.4 million in 2024, then crashed by 1349.31% to -$104.4 million in 2025.
- Its Equity Average was -$104.4 million in Q3 2025, compared to -$69.9 million in Q2 2025 and -$27.6 million in Q1 2025.